Pharma-Bio Serv (PBSV) Downgraded by ValuEngine

ValuEngine cut shares of Pharma-Bio Serv (OTCMKTS:PBSV) from a hold rating to a sell rating in a research note issued to investors on Wednesday.

Pharma-Bio Serv stock opened at $0.45 on Wednesday. The stock has a market cap of $10.38, a price-to-earnings ratio of -7.50 and a beta of 0.39. Pharma-Bio Serv has a 52 week low of $0.33 and a 52 week high of $0.70.

Pharma-Bio Serv (OTCMKTS:PBSV) last released its earnings results on Monday, January 29th. The company reported ($0.02) EPS for the quarter. The company had revenue of $3.63 million for the quarter. Pharma-Bio Serv had a negative net margin of 23.46% and a negative return on equity of 18.22%. equities research analysts forecast that Pharma-Bio Serv will post -0.12 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Pharma-Bio Serv (PBSV) Downgraded by ValuEngine” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/22/pharma-bio-serv-pbsv-downgraded-by-valuengine.html.

Pharma-Bio Serv Company Profile

Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm with a laboratory testing facility in Puerto Rico, the United States, Europe, and Brazil markets. It provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products in Puerto Rico, the United States, Europe, and Brazil.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Pharma-Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma-Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply